secwatch.observer — SEC 8-K summary
======================================

Issuer:     VACCINEX, INC. (VCNX)
CIK:        0001205922
Form:       8-K
Filed at:   2024-06-06T23:59:59+00:00
Accession:  0001193125-24-155612
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaccinex completes last patient visit in SIGNAL-AD Phase 1b/2 Alzheimer's study
-------------------------------------------------------------------------------

- Last patient completed final visit in randomized, double-blind Phase 1b/2 SIGNAL-AD study of pepinemab for Alzheimer's disease.
- Database lock expected in June; key outcomes including safety, FDG-PET, and plasma GFAP biomarkers to be reported in July.
- Pepinemab targets SEMA4D to inhibit astrocyte reactivity and neuroinflammation, a differentiated mechanism vs. anti-amyloid antibodies.
- Study funded by $4.75M from ADDF and $0.75M grant from Alzheimer's Association.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1205922/000119312524155612/0001193125-24-155612-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1205922/000119312524155612/d756458d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-155612

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer